Apyx Medical Corporation (APYX): Price and Financial Metrics

Apyx Medical Corporation (APYX): $1.46

0.09 (-5.81%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

C

APYX Price/Volume Stats

Current price $1.46 52-week high $7.97
Prev. close $1.55 52-week low $1.21
Day low $1.40 Volume 18,700
Day high $1.54 Avg. volume 152,865
50-day MA $1.92 Dividend yield N/A
200-day MA $3.05 Market Cap 50.58M

APYX Stock Price Chart Interactive Chart >


Apyx Medical Corporation (APYX) Company Bio


Apyx Medical Corporation, a energy technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. It operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). The company develops J-Plasma, a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue. It markets and sells Helium Plasma Technology under the Renuvion brand name in the cosmetic surgery market and under the J-Plasma brand name in the hospital surgical market. The company's Renuvion cosmetic technology enables plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue; and the J-Plasma system allows surgeons to operate in eliminating unintended tissue trauma. It also designs, develops, manufactures, and sells electrosurgical and OEM generators and related accessories for medical device manufacturers. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.


APYX Latest News Stream


Event/Time News Detail
Loading, please wait...

APYX Latest Social Stream


Loading social stream, please wait...

View Full APYX Social Stream

Latest APYX News From Around the Web

Below are the latest news stories about APYX MEDICAL CORP that investors may wish to consider to help them evaluate APYX as an investment opportunity.

Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer

CLEARWATER, Fla., November 28, 2023--Apyx Medical Corporation (Nasdaq:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023. Mr. Hill succeeds Tara Semb, whose departure was announced by the Company on November 9, 2023.

Yahoo | November 28, 2023

Apyx Medical Corporation (NASDAQ:APYX) Q3 2023 Earnings Call Transcript

Apyx Medical Corporation (NASDAQ:APYX) Q3 2023 Earnings Call Transcript November 9, 2023 Apyx Medical Corporation misses on earnings expectations. Reported EPS is $-0.13 EPS, expectations were $-0.1. Operator: Please stand by. Hello, and welcome, ladies and gentlemen, to the Third Quarter of Fiscal Year 2023 Earnings Conference Call for Apyx Medical Corporation. At this time, […]

Yahoo | November 10, 2023

Apyx Medical Corp (APYX) Reports 31% Revenue Growth in Q3; Updates Full Year Outlook

Advanced Energy Sales Surge as Company Adjusts Annual Guidance

Yahoo | November 9, 2023

Apyx Medical Corporation Announces New Debt Facility with Perceptive Advisors

CLEARWATER, Fla., November 09, 2023--Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that the Company and its subsidiaries have entered into a new, five-year credit agreement with Perceptive Credit Holdings IV, LP ("Perceptive"), an affiliate of Perceptive Advisors. The Perceptive Credit Agreement provides for a facility of up to $45 million in senior secured term

Yahoo | November 9, 2023

Apyx Medical Corporation Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Outlook

CLEARWATER, Fla., November 09, 2023--Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its third quarter ended September 30, 2023, and updated its financial expectations for the full year ending December 31, 2023.

Yahoo | November 9, 2023

Read More 'APYX' Stories Here

APYX Price Returns

1-mo -18.44%
3-mo N/A
6-mo -43.41%
1-year -51.33%
3-year -85.09%
5-year -59.89%
YTD -44.27%
2023 11.97%
2022 -81.75%
2021 78.06%
2020 -14.89%
2019 30.56%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!